INVESTIGATING MOLECULAR MECHANISM OF VITAMIN D REGULATING BREAST CANCER AND CERVICAL CANCER

Abstract

The prevalence of breast and cervical cancer in women is high worldwide. Breast and cervical cancer are studied extensively to identify their risk factors. One of these risk factors is considered to be a vitamin D deficiency whose molecular mechanism of inhibiting the cancer is not fully understood. The steroid hormone 1, 25-dihydroxyvitamin D3 is thought to effectively prevent and manage each of the aforementioned malignancies. In this study, synergestic effect of varying concentration of cholecalciferol and Fulvestrant on MCF-7 (breast cancer cell line) and HeLa (cervical cancer cell line) was evaluated by using cell viability assay (MTT assay). Furthermore, this study demonstrated how the chou-talalay approach can be used to find synergy between vitamin D and Fulvestrant. In fact, cholecalciferol elevated the percentage cytotoxicity of Fulvestrant to some extent. Cholecalciferol is a powerful anti oxidant and anti-inflammatory, and it may also be able to reduce the body's oxidative stress and inflammation as a result of cancer. Anti-inflammatory efficacy was assessed using the inhibition of protein denaturation assay and the stability of human red blood cells assay while antioxidant activity was assessed using the DPPH free radical scavenging assay. Anticancer activity of cholecalciferol alone and with Fulvestrant in synergy was assessed, which showed that cholecalciferol enhanced the anti-cancer activity of Fulvestrant when used in combination. In addition, it is safe to use within biological limits and can act as antioxidant and anti-inflammatory. So we can say vitamin D can be used an adjuvant therapy to treat cancer which can further be assessed in animal models of various cancer types